Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1

[1]  F. Berthold,et al.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Adamson,et al.  Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. MacDonald,et al.  Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[5]  J. Strominger,et al.  TGF‐β affects development and differentiation of human natural killer cell subsets , 2010, European journal of immunology.

[6]  Michael L. Wang,et al.  Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo , 2009, American journal of hematology.

[7]  Lisa Morrison,et al.  Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. , 2009, Blood.

[8]  S. Asgharzadeh,et al.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. , 2009, The Journal of clinical investigation.

[9]  M. Caligiuri,et al.  The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia , 2009, British journal of haematology.

[10]  M. Caligiuri,et al.  TGF-β Utilizes SMAD3 to Inhibit CD16-Mediated IFN-γ Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells1 , 2008, The Journal of Immunology.

[11]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[12]  D. Keskin,et al.  TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16− NK cells with similarities to decidual NK cells , 2007, Proceedings of the National Academy of Sciences.

[13]  Antonio Ortega,et al.  Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. , 2006, Journal of the National Cancer Institute.

[14]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[15]  M. Caligiuri,et al.  Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. , 2006, Immunity.

[16]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[17]  N. Munshi,et al.  Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. , 2005, Cancer research.

[18]  M. Czuczman,et al.  Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model , 2005, Clinical Cancer Research.

[19]  P. Richardson,et al.  Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application , 2005, British journal of haematology.

[20]  Dong-Wan Kim,et al.  Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients , 2004 .

[21]  M. Weller,et al.  RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo , 2004, Cancer Research.

[22]  Dong-Wan Kim,et al.  Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1 , 2004, The Journal of Immunology.

[23]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[24]  H. Pandha,et al.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers , 2004, British Journal of Cancer.

[25]  R. Seeger,et al.  Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating , 2000, Cancer Immunology, Immunotherapy.

[26]  S. Groshen,et al.  Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. , 1998, Cancer research.

[27]  G. Trinchieri,et al.  Regulation of NK cell functions by TGF-beta 1. , 1995, Journal of immunology.

[28]  P. Stern,et al.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity , 1994, Cancer Immunology, Immunotherapy.

[29]  M. Miyasaka,et al.  Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice , 1993, The Journal of experimental medicine.

[30]  E. Frenkel,et al.  Characterization of human neuroblastoma cell lines established before and after therapy. , 1986, Journal of the National Cancer Institute.

[31]  R. Seeger,et al.  Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. , 1982, Journal of immunology.

[32]  W. Benedict,et al.  Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. , 1977, Cancer research.

[33]  Lei Wu,et al.  Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers , 2010, Cancer Immunology, Immunotherapy.

[34]  A. Bloem,et al.  Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. , 2009, Leukemia research.

[35]  M. Caligiuri,et al.  TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. , 2008, Journal of immunology.